stride trial semaglutide - and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes ๐ดThe STRIDE trial! ๐โคต๏ธ ๐นThe
Description
The development follows the recent expiry of the patent for semaglutide, a key drug used globally to manage both diabetes and obesity triggering a surge of affordable alternatives from domestic pharmaceutical companies
A quick quiz that returns tailored questions to bring to your clinician and red flags to avoid online
The purpose of this review is two-fold: (1) to discuss a case report of idiopathic intracranial hypertension (IIH) after abrupt cessation of a glucagon-like peptide-1 (GLP-1) receptor agonist with resultant rapid weight gain and (2) to review the ...
Correct routing will be critical to helping eligible Medicare patients access treatment
A new federal initiative aims to lower GLP-1 medication costs for Medicare beneficiaries
Sharon Mann has lost nearly 30 pounds since starting on Mounjaro, a GLP-1 medication
